SEAGEN INC (SGEN)
US81181C1045 - Common Stock
Overall SGEN gets a fundamental rating of 4 out of 10. We evaluated SGEN against 588 industry peers in the Biotechnology industry. No worries on liquidiy or solvency for SGEN as it has an excellent financial health rating, but there are worries on the profitability. SGEN is valued quite expensive, but it does show an excellent growth.
1. Profitability
1.1 Basic Checks
In the past year SGEN has reported negative net income.
In the past year SGEN has reported a negative cash flow from operations.
In the past 5 years SGEN reported 4 times negative net income.
In the past 5 years SGEN reported 4 times negative operating cash flow.
1.2 Ratios
With an excellent Return On Assets value of -20.64%, SGEN belongs to the best of the industry, outperforming 82.06% of the companies in the same industry.
SGEN has a Return On Equity of -29.41%. This is amongst the best in the industry. SGEN outperforms 81.40% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -20.64% | ||
| ROE | -29.41% | ||
| ROIC | N/A |
ROA(3y)-6.47%
ROA(5y)-8.28%
ROE(3y)-8.73%
ROE(5y)-10.42%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
SGEN's Gross Margin of 75.39% is amongst the best of the industry. SGEN outperforms 84.88% of its industry peers.
SGEN's Gross Margin has declined in the last couple of years.
SGEN does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 75.39% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-5.99%
GM growth 5Y-2.28%
2. Health
2.1 Basic Checks
SGEN does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for SGEN has been increased compared to 1 year ago.
The number of shares outstanding for SGEN has been increased compared to 5 years ago.
There is no outstanding debt for SGEN. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
An Altman-Z score of 23.31 indicates that SGEN is not in any danger for bankruptcy at the moment.
SGEN has a better Altman-Z score (23.31) than 94.68% of its industry peers.
SGEN has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 23.31 |
ROIC/WACCN/A
WACC10.94%
2.3 Liquidity
SGEN has a Current Ratio of 2.67. This indicates that SGEN is financially healthy and has no problem in meeting its short term obligations.
With a Current ratio value of 2.67, SGEN is not doing good in the industry: 73.26% of the companies in the same industry are doing better.
SGEN has a Quick Ratio of 2.12. This indicates that SGEN is financially healthy and has no problem in meeting its short term obligations.
The Quick ratio of SGEN (2.12) is worse than 76.91% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.67 | ||
| Quick Ratio | 2.12 |
3. Growth
3.1 Past
The earnings per share for SGEN have decreased strongly by -16.23% in the last year.
SGEN shows a strong growth in Revenue. In the last year, the Revenue has grown by 23.40%.
The Revenue has been growing by 32.40% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)-16.23%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q-11.65%
Revenue 1Y (TTM)23.4%
Revenue growth 3Y28.88%
Revenue growth 5Y32.4%
Revenue growth Q2Q27.12%
3.2 Future
The Earnings Per Share is expected to grow by 32.31% on average over the next years. This is a very strong growth
The Revenue is expected to grow by 26.49% on average over the next years. This is a very strong growth
EPS Next Y-28.74%
EPS Next 2Y17.92%
EPS Next 3Y29.83%
EPS Next 5Y32.31%
Revenue Next Year28.4%
Revenue Next 2Y30.41%
Revenue Next 3Y29.91%
Revenue Next 5Y26.49%
3.3 Evolution
The Revenue growth rate is stable: in the next years the growth will be about the same than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
SGEN reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for SGEN. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
SGEN's earnings are expected to grow with 29.83% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y17.92%
EPS Next 3Y29.83%
5. Dividend
5.1 Amount
No dividends for SGEN!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
SEAGEN INC
NASDAQ:SGEN (12/13/2023, 7:12:24 PM)
After market: 228.95 +0.21 (+0.09%)228.74
-0.16 (-0.07%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap43.15B
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -20.64% | ||
| ROE | -29.41% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 75.39% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.63
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 2.67 | ||
| Quick Ratio | 2.12 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)-16.23%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y-28.74%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)23.4%
Revenue growth 3Y28.88%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y